Pharma channel feed

Af­ter CRL in 2022, Pfiz­er and OP­KO get FDA nod for pe­di­atric growth hor­mone de­fi­cien­cy med

Last year
FDA+

As­traZeneca ex­pands tree-plant­i­ng ini­tia­tive with an­oth­er $400M to plant 200M trees by 2030

Last year

FDA, EMA ac­cept Pfiz­er's he­mo­phil­ia B gene ther­a­py, set­ting up show­down with CSL Behring

Last year
FDA+

UK’s NICE wants more ef­fec­tive­ness da­ta on Lil­ly’s tirzepatide

Last year

What got on­col­o­gy ex­perts talk­ing and tweet­ing at AS­CO? Har­ris Poll sur­vey finds it was more than just da­ta

Last year
Marketing

Mar­ket­ingRx roundup: Pfiz­er re­ups sick­le cell cam­paign with NFL play­er; Alk­er­mes aims for bipo­lar pa­tients with TV ad

Last year
Marketing

Af­ter cut­ting back on Vuity last fall, Ab­b­Vie culls a sec­ond-gen pres­by­opia eye drop

Last year
R&D

Rep. Pal­lone push­es House Re­pub­li­cans to ad­dress drug short­ages in PAH­PA reau­tho­riza­tion

Last year
Manufacturing

J&J touts PhII da­ta in rare blood dis­or­der as it plots a piv­otal study

Last year
R&D

UK's Na­tion­al Can­cer Re­search In­sti­tute to shut down, cit­ing 'risk of op­er­a­tional fail­ure'

Last year

Pfiz­er’s alope­cia tablet ap­proved by FDA in adults and teens, win­ning broad­er mar­ket than Lil­ly's Olu­mi­ant

Last year
FDA+

GSK set­tles key Zan­tac case ahead of tri­al

Last year
Law

Pfiz­er picks GLP-1 tablet win­ner: Danuglipron for PhI­II

Last year
R&D

Eli Lil­ly's tirzepatide is the king of the GLP-1s, but oth­er op­tions are com­ing

Last year

CHMP rec­om­mends Ab­b­Vie's mi­graine drug, GSK's ane­mia treat­ment

Last year

FDA is­sues draft guid­ance for clin­i­cal re­search in­to psy­che­delics

Last year
Discovery
FDA+

Jazz sues FDA, HHS over ri­val nar­colep­sy drug ap­proval

Last year
Law

Vi­iV grows HIV pre­ven­tion cam­paign with new in­flu­encers, in­clud­ing ac­tor Taye Dig­gs

Last year
Marketing

Medicare spells out what the new Alzheimer's drug reg­istries will col­lect

Last year

In­ter­cep­t's NASH drug is again re­ject­ed by FDA, lead­ing the com­pa­ny to re­struc­ture in piv­ot from dis­ease

Last year
FDA+

MPP signs on four gener­ics mak­ers to make No­var­tis' Tasigna more ac­ces­si­ble

Last year
Deals

Eli Lil­ly and di­a­betes as­so­ci­a­tion team up with MLB play­er to pro­mote its in­sulin cost cap

Last year
Marketing

EMA asks for more in­for­ma­tion af­ter safe­ty sig­nal aris­es for GLP-1s, semaglu­tide in thy­roid can­cer

Last year

Ab­b­Vie spurs em­ploy­ee gen­eros­i­ty with week­long vol­un­teer­ing ini­tia­tive

Last year
Marketing
First page Previous page 114115116117118119120 Next page Last page
A service from the Financial Times